{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:52:51Z","timestamp":1788965571977,"version":"build-2803163510"},"reference-count":25,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T00:00:00Z","timestamp":1517788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Med Imag Rad Onc"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">TROG<\/jats:styled-content> 09.03 prospectively studied the utility of Fluorine\u201018 Fluorodeoxyglucose (18\u2010<jats:styled-content style=\"fixed-case\">FDG<\/jats:styled-content>) <jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content> in the management of Merkel cell carcinoma of skin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Following consent and registration, a pre\u2010treatment <jats:styled-content style=\"fixed-case\">FDG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content> was performed. Sites of avid disease were confirmed by cytology where practicable. Following surgery, patients with <jats:styled-content style=\"fixed-case\">AJCC<\/jats:styled-content>v7 Stages <jats:styled-content style=\"fixed-case\">IIA<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IIIB<\/jats:styled-content> disease were treated with chemo\u2010radiotherapy and reassessed with a post\u2010treatment <jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty\u2010eight subjects (45 males and 13 females, median age 68\u00a0years) were enrolled between 2011 and 2015, 43 patients of whom went on to receive chemo\u2010radiotherapy. An occult primary was present in 22 (37.9%), T1 in 22 (37.9%) and T2 disease in 14 (24.1%). Nodal disease was present in 69% of cases. Fifty per cent of subjects had gross residual disease at the primary site and\/or nodal site at the time of registration. 18\u2010<jats:styled-content style=\"fixed-case\">FDG PET<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content> had a sensitivity of 94.74% (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 82\u201399.3%) and a specificity of 88.24% (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 63.56\u201398.54). The positive predictive value was 94.74% (83.01\u201398.51) and the negative predictive value was 88.24% (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 65.81\u201396.69). The pre\u2010treatment <jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content> influenced a treatment decision in 27.6% of cases. Upstaging occurred in 15 (25.9%), with no down staging. Other diseases were identified in 4 (6.9%) patients. Univariate analysis failed to demonstrate that pre\u2010treatment <jats:styled-content style=\"fixed-case\">SUV<\/jats:styled-content> levels or a negative post\u2010treatment <jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content> had any impact on overall survival. <jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content> staged patients had 89% 3\u2010year in\u2010field loco\u2010regional control and 76% 3\u2010year overall survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Staging 18\u2010<jats:styled-content style=\"fixed-case\">FDG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content> significantly influenced treatment decisions in approximately one\u2010third of cases of <jats:styled-content style=\"fixed-case\">MCC<\/jats:styled-content> and should be considered in the routine pre\u2010treatment work\u2010up. Post\u2010treatment <jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content> was not found to be prognostic. Funding through the Medicare Benefits Schedule needs to be considered for high risk <jats:styled-content style=\"fixed-case\">MCC<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1754-9485.12705","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T04:46:55Z","timestamp":1517892415000},"page":"412-419","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Prospective analysis of the utility of 18\u2010<scp>FDG PET<\/scp> in Merkel cell carcinoma of the skin: A Trans Tasman Radiation Oncology Group Study, <scp>TROG<\/scp> 09:03"],"prefix":"10.1111","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3410-1382","authenticated-orcid":false,"given":"Michael","family":"Poulsen","sequence":"first","affiliation":[{"name":"Radiation Oncology Princess Alexandra Raymond Tce (ROPART) South Brisbane Queensland Australia"},{"name":"School of Medicine The University of Queensland Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Macfarlane","sequence":"additional","affiliation":[{"name":"School of Medicine The University of Queensland Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0106-8325","authenticated-orcid":false,"given":"Michael","family":"Veness","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Westmead Hospital Sydney University of Sydney Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venessa","family":"Estall","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre Melbourne Victoria Australia"},{"name":"University of Melbourne Melbourne Victoria Australia"},{"name":"Department of Radiation Oncology Liverpool Hospital Sydney Liverpool New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Hruby","sequence":"additional","affiliation":[{"name":"Royal Brisbane and Women's Hospital Brisbane Queensland Australia"},{"name":"Royal Prince Alfred Hospital Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Calvary Mater Newcastle Newcastle New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Pullar","sequence":"additional","affiliation":[{"name":"Radiation Oncology Princess Alexandra Raymond Tce (ROPART) South Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Tripcony","sequence":"additional","affiliation":[{"name":"School of Medicine The University of Queensland Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Rischin","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre Melbourne Victoria Australia"},{"name":"University of Melbourne Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,5]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(04)01593-1"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1288\/00005537-199203000-00003"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.124"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.154"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000000523"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.06.021"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-013-0040-x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.02.076"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.116814"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.08.042"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12400"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.158261"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603702"},{"key":"e_1_2_6_15_1","first-page":"156","article-title":"Cutaneous Merkel cell carcinoma: role of 18FDG PET\u2010CT","volume":"23","author":"Amal G","year":"2016","journal-title":"Pan Afr Med J"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000000039"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0b013e318281658e"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0b013e31825ae8e7"},{"key":"e_1_2_6_19_1","first-page":"347","article-title":"Clinical added\u2010value of 18FDG PET in neuroendocrine\u2010Merkel cell carcinoma","volume":"16","author":"Belhocine T","year":"2006","journal-title":"Oncol Rep"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.05.067"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.08.011"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2012.04.007"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)E0145-A"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970901)80:5<881::AID-CNCR8>3.0.CO;2-O"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9610(97)00193-1"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-2197.1998.tb04771.x"}],"container-title":["Journal of Medical Imaging and Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1754-9485.12705","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1754-9485.12705","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T12:49:10Z","timestamp":1695473350000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1754-9485.12705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,5]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1111\/1754-9485.12705"],"URL":"https:\/\/doi.org\/10.1111\/1754-9485.12705","archive":["Portico"],"relation":{},"ISSN":["1754-9477","1754-9485"],"issn-type":[{"value":"1754-9477","type":"print"},{"value":"1754-9485","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,5]]},"assertion":[{"value":"2017-10-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}